Organon
As of the edition of 20 October 2026, Organon runs 66 drugs, 60 of them marketed; it is on route A at 4 targets and on route B at 26 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Organon was acquired in 2026; successor SUN PHARMACEUTICAL INDUSTRIES INC.
The records place 11 company names in this family.
- Organon Usa Inc: acquired in 2021; successor Organon and Co
- Organon USA Inc., a subsidiary of Merck & Co., Inc.: acquired in 2021; successor Organon and Co
- Organon and Co: acquired in 2026; successor SUN PHARMACEUTICAL INDUSTRIES INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 60 |
| Went quiet | 3 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 66 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Atorvastatin | none listed | 4 |
| Cholecalciferol | none listed | 2 |
| Simvastatin | none listed | 3 |
| Ezetimibe | none listed | 3 |
| Losartan | none listed | 1 |
| Hydrochlorothiazide | none listed | 4 |
| Ethinyl estradiol | none listed | 5 |
| Montelukast | none listed | 1 |
| Levodopa | none listed | 4 |
| Sugammadex | Ends 2028 (exclusivity) | 0 |
| Heparin | none listed | 5 |
| Rocuronium | none listed | 0 |
| Mometasone furoate | none listed | 3 |
| Alendronic acid | none listed | 3 |
| Gentamicin | none listed | 0 |
| Corticotropin | none listed | 1 |
| Clindamycin | none listed | 0 |
| Etoricoxib | none listed | 1 |
| Gonadotropin, chorionic | Ended 1985 (computed from the first US licence) | 0 |
| Mirtazapine | none listed | 10 |
| Desloratadine | none listed | 3 |
| Betamethasone | none listed | 6 |
| Pseudoephedrine | none listed | 4 |
| Corifollitropin alfa | none listed | 0 |
A route B row is one company at one target. 35 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 4 targets, route B at 26 targets.
All 30 rows on route A or B
In the product30 company-target rows on route A or B; 27 are not shown here, and no score is.
See all 30 targets where Organon needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 28 trials led
- Mental health: 28 trials led
- Immune system: 23 trials led